This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gallmeier, E. Articles by Kern, S. E. Search for Related Content PubMed PubMed Citation Articles by Gallmeier, E. Articles by Kern, S. E.

Targeting Fanconi Anemia/BRCA2 Pathway Defects in Cancer: The Significance of Preclinical Pharmacogenomic Models

Authors' Affiliation: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland

Requests for reprints: Scott E. Kern, Department of Oncology, Johns Hopkins University, Cancer Research Building 464, 1650 Orleans Street, Baltimore, MD 21231. Phone: 410-614-3314; Fax: 443-287-4653; E-mail: sk{at}jhmi.edu.

Abstract

Defects in the Fanconi anemia (FA) pathway occur in subsets of diverse human cancers. The hypersensitivity of FA pathway-deficient cells to DNA interstrand cross-linking and possibly other agents renders these genes attractive targets for a genotype-based, individualized anticancer therapy. A prerequisite before clinical trials is the validation and quantification of this hypersensitivity in suitable preclinical pharmacogenomic models. In addition, the effects of combinational therapy need to be evaluated and novel agents sought. We discuss here the pitfalls and limitations in the interpretation of common FA models when applied to the validation of FA gene defects as therapeutic targets. In general, all preclinical models are prone to certain artifacts and, thus, promising results in a single or few models rarely translate into clinical success. Nevertheless, the extraordinary robustness of FA pathway-deficient cells to interstrand cross-linking agents, which are observable in virtually any model independent of species, cell type, or technique used to engineer the gene defect, in various in vitro and in vivo settings, renders these gene defects particularly attractive for targeted therapy. Clinical trials are now under way.

This article has been cited by other articles:

				T. Hucl, C. Rago, E. Gallmeier, J. R. Brody, M. Gorospe, and S. E. Kern A Syngeneic Variance Library for Functional Annotation of Human Variation: Application to BRCA2 Cancer Res., July 1, 2008; 68(13): 5023 - 5030. [Abstract] [Full Text] [PDF]

				E. Gallmeier, T. Hucl, J. R. Brody, D. A. Dezentje, K. Tahir, J. Kasparkova, V. Brabec, K. E. Bachman, and S. E. Kern High-Throughput Screening Identifies Novel Agents Eliciting Hypersensitivity in Fanconi Pathway-Deficient Cancer Cells Cancer Res., March 1, 2007; 67(5): 2169 - 2177. [Abstract] [Full Text] [PDF]